https://www.selleckchem.com/products/chitosan-oligosaccharide.html 12 mMt for Nepal in 2019. Nepal contributes about 0.06% CO2 emission from cement production to the global CO2 emission (2.08 Gt) from the cement industry. By evaluating per capita gross domestic product (GDP) (from 1987/1988 to 2019/2020) and the human development index (HDI) (from 1990 to 2019) with the cement production, the result shows that cement production increases significantly (p less then 0.01) with an increase in the GDP and the HDI. We emphasize that the study's outputs are directly relevant to the country's emission inventory, mitigation planning, and developing a strategy for cleaner production. Gram-negative nosocomial pneumonia (NP), including hospital-acquired bacterial pneumonia (HABP), ventilated HABP (vHABP), and ventilator-associated bacterial pneumonia (VABP), is a significant cause of morbidity and mortality. Common pathogens, including Enterobacterales and Pseudomonas aeruginosa, are prevalent in healthcare settings and have few effective treatment options due to high rates of antibacterial resistance. Resistant pathogens are associated with significantly worse outcomes, relative to patients with susceptible infections. Ceftolozane/tazobactam (C/T) has established efficacy in clinical trials of patients with NP. This review aims to collate data on C/T use for HABP/vHABP/VABP infections in real-world clinical practice. This systematic literature review searched online biomedical databases for real-world studies of C/T used to treat Gram-negative respiratory tract infections (RTIs) between January 2009 and June 2020. Thirty-three studies comprising 658 patients were identified. Pneumonidemonstrate that C/T shows similar outcomes as those seen in clinical trials, despite the higher frequency of multidrug-resistant pathogens, and comorbidities that may have been excluded from the trials. The studies identified in this review demonstrate that C/T shows similar outcomes as those see